304 related articles for article (PubMed ID: 18599281)
1. HMGB1: a two-headed signal regulating tumor progression and immunity.
Campana L; Bosurgi L; Rovere-Querini P
Curr Opin Immunol; 2008 Oct; 20(5):518-23. PubMed ID: 18599281
[TBL] [Abstract][Full Text] [Related]
2. High-mobility group box 1 (HMGB1) protein: friend and foe.
Ulloa L; Messmer D
Cytokine Growth Factor Rev; 2006 Jun; 17(3):189-201. PubMed ID: 16513409
[TBL] [Abstract][Full Text] [Related]
3. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
Dong Xda E; Ito N; Lotze MT; Demarco RA; Popovic P; Shand SH; Watkins S; Winikoff S; Brown CK; Bartlett DL; Zeh HJ
J Immunother; 2007 Sep; 30(6):596-606. PubMed ID: 17667523
[TBL] [Abstract][Full Text] [Related]
4. RAGE and TLRs: relatives, friends or neighbours?
Ibrahim ZA; Armour CL; Phipps S; Sukkar MB
Mol Immunol; 2013 Dec; 56(4):739-44. PubMed ID: 23954397
[TBL] [Abstract][Full Text] [Related]
5. Immunogenic cancer cell death: a key-lock paradigm.
Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
[TBL] [Abstract][Full Text] [Related]
6. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.
Apetoh L; Ghiringhelli F; Tesniere A; Criollo A; Ortiz C; Lidereau R; Mariette C; Chaput N; Mira JP; Delaloge S; André F; Tursz T; Kroemer G; Zitvogel L
Immunol Rev; 2007 Dec; 220():47-59. PubMed ID: 17979839
[TBL] [Abstract][Full Text] [Related]
7. HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells.
Wild CA; Bergmann C; Fritz G; Schuler P; Hoffmann TK; Lotfi R; Westendorf A; Brandau S; Lang S
Int Immunol; 2012 Aug; 24(8):485-94. PubMed ID: 22473704
[TBL] [Abstract][Full Text] [Related]
8. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.
Apetoh L; Tesniere A; Ghiringhelli F; Kroemer G; Zitvogel L
Cancer Res; 2008 Jun; 68(11):4026-30. PubMed ID: 18519658
[TBL] [Abstract][Full Text] [Related]
9. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors.
Romagne F
Drug Discov Today; 2007 Jan; 12(1-2):80-7. PubMed ID: 17198976
[TBL] [Abstract][Full Text] [Related]
10. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).
van Beijnum JR; Buurman WA; Griffioen AW
Angiogenesis; 2008; 11(1):91-9. PubMed ID: 18264787
[TBL] [Abstract][Full Text] [Related]
11. High-mobility group box-1 in sterile inflammation.
Tsung A; Tohme S; Billiar TR
J Intern Med; 2014 Nov; 276(5):425-43. PubMed ID: 24935761
[TBL] [Abstract][Full Text] [Related]
12. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity.
Bianchi ME; Manfredi AA
Immunol Rev; 2007 Dec; 220():35-46. PubMed ID: 17979838
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis.
Foell D; Wittkowski H; Roth J
Nat Clin Pract Rheumatol; 2007 Jul; 3(7):382-90. PubMed ID: 17599072
[TBL] [Abstract][Full Text] [Related]
14. Immunogenic death of colon cancer cells treated with oxaliplatin.
Tesniere A; Schlemmer F; Boige V; Kepp O; Martins I; Ghiringhelli F; Aymeric L; Michaud M; Apetoh L; Barault L; Mendiboure J; Pignon JP; Jooste V; van Endert P; Ducreux M; Zitvogel L; Piard F; Kroemer G
Oncogene; 2010 Jan; 29(4):482-91. PubMed ID: 19881547
[TBL] [Abstract][Full Text] [Related]
15. Masquerader: high mobility group box-1 and cancer.
Ellerman JE; Brown CK; de Vera M; Zeh HJ; Billiar T; Rubartelli A; Lotze MT
Clin Cancer Res; 2007 May; 13(10):2836-48. PubMed ID: 17504981
[TBL] [Abstract][Full Text] [Related]
16. Molecular characteristics of immunogenic cancer cell death.
Tesniere A; Panaretakis T; Kepp O; Apetoh L; Ghiringhelli F; Zitvogel L; Kroemer G
Cell Death Differ; 2008 Jan; 15(1):3-12. PubMed ID: 18007663
[TBL] [Abstract][Full Text] [Related]
17. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity.
Lotze MT; Zeh HJ; Rubartelli A; Sparvero LJ; Amoscato AA; Washburn NR; Devera ME; Liang X; Tör M; Billiar T
Immunol Rev; 2007 Dec; 220():60-81. PubMed ID: 17979840
[TBL] [Abstract][Full Text] [Related]
18. Role of high mobility group box 1 in inflammatory disease: focus on sepsis.
Bae JS
Arch Pharm Res; 2012 Sep; 35(9):1511-23. PubMed ID: 23054707
[TBL] [Abstract][Full Text] [Related]
19. Witch hunt against tumor cells enhanced by dendritic cells.
Locher C; Rusakiewicz S; Tesnière A; Ghiringhelli F; Apetoh L; Kroemer G; Zitvogel L
Ann N Y Acad Sci; 2009 Sep; 1174():51-60. PubMed ID: 19769736
[TBL] [Abstract][Full Text] [Related]
20. The immunogenicity of tumor cell death.
Kepp O; Tesniere A; Zitvogel L; Kroemer G
Curr Opin Oncol; 2009 Jan; 21(1):71-6. PubMed ID: 19125021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
